Cell and Gene Therapy Manufacturing Services Market worth $26.72 Billion, Globally, by 2030 – Comprehensive Study by The Insight Partners
27 sept. 2023 10h12 HE
|
The Insight Partners
Pune, India, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cell & gene therapy (CGT) programs are rapidly advancing from research & development to clinical trials and commercial approval. Establishing...
Avid Bioservices to Participate in RBC Capital Markets Virtual CDMO Conference
26 sept. 2023 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Societal CDMO to Participate in RBC Capital Markets Virtual CDMO Conference
25 sept. 2023 16h05 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (CDMO)...
Societal CDMO Announces Corporate Restructuring
20 sept. 2023 16h05 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASDAQ: SCTL), a contract development and manufacturing organization (CDMO) dedicated to...
Rentschler Biopharma appoints Benedikt von Braunmuehl as Chief Executive Officer
19 sept. 2023 05h00 HE
|
Rentschler Biopharma SE
Benedikt von Braunmuehl, a transformational leader with a 30-year track record in the global healthcare industry, is named CEO Rentschler Biopharma SECompany also announces appointment of Tom Roberts,...
Global Active Pharmaceutical Ingredients CDMO Market 2023 - 2028: Key Players Driving API CDMO Market Expansion: Cambrex, Patheon, Lonza, Samsung Biologics and More
14 sept. 2023 07h58 HE
|
Research and Markets
Dublin, Sept. 14, 2023 (GLOBE NEWSWIRE) -- The "Active Pharmaceutical Ingredients CDMO Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)" report has been added to ...
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2023
07 sept. 2023 16h05 HE
|
Avid Bioservices, Inc
-- Recorded First Quarter Revenue of $37.7 Million -- -- Signed $36 Million in Net New Business Orders Resulting in a Backlog of $189 Million -- -- Cell and Gene Therapy Facility Expansion Remains...
Societal CDMO Secures Project Expansion Agreements With Several Existing Customers
07 sept. 2023 07h00 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to...
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2024 After Market Close on September 7, 2023
31 août 2023 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Global Cell and Gene Therapy CDMO Market, Focused on AAV, Set to Surge with 24.61% CAGR
30 août 2023 09h33 HE
|
Research and Markets
Dublin, Aug. 30, 2023 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Biomanufacturing CDMO Market - Focused on AAV - A Global and Regional Analysis: Focus on Phase of Development, Workflow,...